Olympus Corp. · TSE:7733
Olympus — Olympus Corp Ord — Q1 2027 Earnings Presentation
32 slides from Olympus's earnings presentation, Aug 7, 2026
Slide 1: Consolidated Financial Results for the 1st Quarter of Fiscal Year 2027
Consolidated Financial Results for the 1st Quarter of Fiscal Year 2027 August 7, 2026 Olympus Corporation | Director, Representative Executive Officer, President and Chief Executive Officer, Bob White | Executive Officer and Chief Financial Officer, Michael Parenti
Slide 2: Disclaimer
Disclaimer ▪ This material contains forward-looking statements that reflect management’s current views, plans, and expectations based on information available at the time of preparation. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, un
Slide 3: Table of Contents
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Table of Contents CEO 1. Executive Summary CEO 2. Strategic Progress CFO 3. Q1 Fiscal Year 2027 Financial Results and Business Review CFO 4. Progress Against Full-Year Guidance 5. Appendix 3
Slide 4: Executive Summary
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Executive Summary 4
Slide 5: Where Purpose Meets Performance: Shaping the Future of Endoscopy-Enabled Care
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Where Purpose Meets Performance: Shaping the Future of Endoscopy-Enabled Care OUR PURPOSE Making people’s lives healthier, safer and more fulfilling OUR STRATEGIC PILLARS Innovation-Driven Growth
Slide 6: Strategic Progress
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Strategic Progress 6
Slide 7: Progress Against Our Strategic Pillars
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Progress Against Our Strategic Pillars Innovation-Driven Growth Simplicity Accountability Lead the next wave of innovation & Simplify Olympus to Support a high-performance culture of expand to fas
Slide 8: FY2027 is Off to a Good Start
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix FY2027 is Off to a Good Start GIS remains growth engine SIS headwind is limited ¥168.4B ¥71.9B Double-digit growth1,2 across North The core franchises (Urology and America, Europe, and APAC confir
Slide 9: Sustained Growth Across Core Markets
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Sustained Growth Across Core Markets North America, Europe, and APAC China and Japan ~80% +21% +9% ~20% -1% -8% of sales YoY1 CC2 of sales YoY1 CC2 ▪ Delivered a second consecutive quarter of doub
Slide 10: Patient Safety Remains Our Unconditional Focus
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Patient Safety Remains Our Unconditional Focus FDA Continuous, constructive engagement with FDA maintained. Olympus remains committed to full transparency with the agency as work progresses Engage
Slide 11: Technology in Action: Delivering Innovation That Advances Care
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Technology in Action: Delivering Innovation That Advances Care Key Drivers1 Launched in FY26 / Planned launches from FY27 onwards GI GI GI/RESP GI GI Potential growth upside through M&A, etc. US C
Slide 12: Consolidated Financial Results and Business Review
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Consolidated Financial Results and Business Review FY2027 Q1 12
Slide 13: Q1 Highlights
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Fiscal Year 2027 Q1 Highlights Highlights Q1 results marked a good start, reinforcing confidence in achieving full-year guidance ¥240.4B ▪ Revenue of ¥240.4B, up 16% (+5% CC), driven by strong GIS
Slide 14: Q1 Gastrointestinal Solutions Division
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Fiscal Year 2027 Q1 Gastrointestinal Solutions Division Medical Service GI Endoscopy Key Factors for Q1 Results (YoY) +15% YoY2 +24% YoY2 Revenue grew 24% year-on-year, led by continued EDOF scope
Slide 15: Q1 Surgical and Interventional Solutions Division
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Fiscal Year 2027 Q1 Surgical and Interventional Solutions Division Other Therapeutic Areas Urology Key Factors for Q1 Results (YoY) -17% YoY2 +14% YoY2 -24% CC3 +2% CC3 Urology delivered 14% year-
Slide 16: Progress Against Full-Year Guidance
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Progress Against Full-Year Guidance FY2027 16
Slide 17: Consolidated Guidance
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Fiscal Year 2027 Consolidated Guidance Revenue ¥1,055.0B ¥1,076.0B FY27 Guidance +1.5% CC2 +3.5% CC 2 +4.4% YoY +6.5% YoY ▪ Full-year guidance 3 3 unchanged from May ▪ 100+ bps of annual Adjusted
Slide 18: OLYMPUS
OLYMPUS
Slide 19: Appendix
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Appendix 19
Slide 20: Q1 Consolidated Financial Results
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Fiscal Year 2027 Q1 Consolidated Financial Results (Billions of yen, except EPS and adjusted EPS) FY26 Q1 FY27 Q1 YoY After FX adjustment Revenue 206.5 240.4 +16% +5% Cost of sales 71.4 83.6 +17%
Slide 21: Q1 Results by Business Segment
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Fiscal Year 2027 Q1 Results by Business Segment (Billions of yen) FY26 Q1 FY27 Q1 YoY After FX adjustment Revenue 139.0 168.4 +21% +10% Operating profit 18.1 38.6 +113% +84% GIS % of revenue 13.0%
Slide 22: Factors that Affected Consolidated Adjusted Operating Profit in Q1
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Factors that Affected Consolidated Adjusted Operating Profit in Fiscal Year 2027 Q1 ▪ GIS: Increased by strong (Billions of yen) performance in North America, Europe and APAC ▪ SIS: Decreased due
Slide 23: Key Product Catalysts: Gastrointestinal Solutions Division
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Key Product Catalysts: Gastrointestinal Solutions Division (As of August 7, 2026) Growth drivers now GI Endoscopy GI EndoTherapy ▪ EVIS X1 system and scopes ▪ ERCP (Guidwires) ▪ EVIS EXERA III sys
Slide 24: Key Product Catalysts: Surgical and Interventional Solutions Division
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Key Product Catalysts: Surgical and Interventional Solutions Division (As of August 7, 2026) Growth drivers now Urology Respiratory Surgical Endoscopy ▪ Resection electrodes with ESG-410 ▪ EVIS X1
Slide 25: Q1 Consolidated Adjusted Operating Profit
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Fiscal Year 2027 Q1 Consolidated Adjusted Operating Profit Adjusted operating profit is the amount after deducting “Other income” and “Other expenses” from operating profit. (Billions of yen) FY26
Slide 26: Consolidated Statement of Financial Position
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Consolidated Statement of Financial Position 1 Total assets decreased due mainly to a decrease in cash and cash equivalents resulting from shareholder returns and BioProtect acquisition, while goo
Slide 27: Consolidated Cash Flows
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Consolidated Cash Flows 1 FCF: Negative ¥49.9 billion due mainly to BioProtect acquisition, despite an increase in profit before tax and lower corporate income tax payments. Adjusted FCF1 was posi
Slide 28: Consolidated Guidance
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Fiscal Year 2027 Consolidated Guidance (Billions of yen, Except EPS and FY26 Full-year FY27 Guidance vs FY26 After FX adjustment Adjusted EPS) Revenue 1,010.7 1,055.0 to 1,076.0 +4.4% to +6.5% +1.
Slide 29: Guidance by Business Segment
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Fiscal Year 2027 Guidance by Business Segment (Billions of yen) FY26 Full-year FY27 Guidance vs FY26 After FX adjustment Revenue 697.4 744.0 to 749.0 +6.7% to +7.4% +3.7% to +4.5% Operating profit
Slide 30: Expenditures: Q1 Actuals and Guidance
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Expenditures: Fiscal Year 2027 Q1 Actuals and Fiscal Year 2027 Guidance (Billions of yen) FY26 Q1 FY27 Q1 FY27 Guidance FY27 (Billions of yen) FY26 Q1 FY27 Q1 Guidance R&D expenditures1 (a) 27.9 2
Slide 31: Foreign Exchange and Sensitivity
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Foreign Exchange and Sensitivity Foreign exchange rate (Yen) FY26 Q1 FY27 Q1 FY27 Guidance Yen/U.S.dollar 144.59 159.49 155 Yen/Euro 163.80 185.39 181 Yen/CNY 19.99 23.43 22.5 Forex sensitivity (a
Slide 32: Acronyms
Table of Executive Strategic Financial Consolidated contents Summary Progress Results Guidance Appendix Acronyms Acronyms Term APAC Asia Pacific BPH Benign Prostatic Hyperplasia EBUS-TBNA Endobronchial Ultrasound-guided Transbronchial Fine Needle Aspiration EMR Endoscopic Mucosal Resection ERCP Endo